Arcturus therapeutics announces third quarter 2023 financial update and pipeline progress

San diego--(business wire)---- $arct #clinicaltrial--arcturus therapeutics holdings inc. (the “company”, “arcturus”, nasdaq: arct), a global late-stage clinical messenger rna medicines company focused on the development of infectious disease vaccines and opportunities within liver and respiratory rare diseases, today announced its financial results for the third quarter ended sept. 30, 2023, and provided corporate updates. “we had considerable progress this quarter expanding our next generation starr® vaccine platform,.
ARCT Ratings Summary
ARCT Quant Ranking